Skip to content
NASDAQ · SURGICAL & MEDICAL INSTRUMENTS & APPARATUS · SMALL CAP

Femasys Inc. FEMY

6 fiscal years on record · USD · FY2025 reported · SEC filings only
$2.3M
▲ 40.8% YoY
$-18.6M
$-19.2M

Slide the table for earlier years · "·" marks a figure not available in our data for that year.

In brief

What this company does

The Company is a U.S. manufacturer that has received global regulatory approvals for its product portfolio, which is currently being commercialized in the U.S. and key international markets. Femasys Inc. was incorporated in Delaware on February 19, 2004 and is headquartered in Suwanee, Georgia. As of December 31, 2025, we employed 51 full-time employees and 3 part-time employees.

Written from the business description in Femasys Inc.'s annual report to the U.S. Securities and Exchange Commission, filed 31 March 2026. Every sentence was checked against that document before publication.

Growth

USD 2.3M
Revenue, FY2025 · full 6-year series below
Revenue $M Net income $M
FY2025 · Revenue 2.3 · Net income -18.6
1M2M-10M-20M
202020232025
Compound annual growth
+23.9%
+17.2%
3 yrs
5 yrs
10 yrs
15 yrs

Revenue compounded at +17.2% a year over the five years to FY2025.

Compound annual rates per period — left blank where that exact year isn't on file, the series crosses a loss, or (per-share rows) a split falls inside the window.

Profitability

−812 cents
lost on every revenue dollar
Operating margin Net margin
FY2025 · Operating -767.0% · Net -812.3%
-500%-1000%
202020222025
ROE
FY2025 · ROE -455.8%
-200%-400%
202020222025
Three returns, three denominators.

Each USD of equity lost 456 cents this year.

Cash & shareholders

·
returned in FY2025 · dividends + net buybacks
Free cash flow $M
FY2025 · FCF -19.2
-10M-20M
202020222025
Net buybacks $M Dividends $M
FY2024 · Dividends · · Net buybacks -2.0
-3M-6M
202220232024

Total assetsUSD 20.7M
EquityUSD 5.9M
CashUSD 9.3M
Current ratio4.53×

Equity funds 28% of total assets.

The 6-year record

6 fiscal years
Every figure from documents filed with the SEC · USD

EPS, diluted, dividend per share and shares outstanding are shown without shading, and a vertical line marks the year the share count changed — the series crosses a large, unexplained change in share count, so the years on either side are not on a comparable scale.

row low → row highnegative—not applicable◌not available in our data
FEMY, 6-year financial record
Metric 202520242023202220212020
Revenue $B0.00.00.00.00.00.0
Operating income $B−0.0−0.0−0.0−0.0−0.0−0.0
EBITDA $B−0.0−0.0−0.0−0.0−0.0−0.0
Income tax $B0.00.00.00.00.00.0
Net income $B−0.0−0.0−0.0−0.0−0.0−0.0
Free cash flow $B−0.0−0.0−0.0−0.0−0.0−0.0
EPS, diluted $−0.47−0.85−0.93−0.96−1.12−7.20
Dividend / sh $◌◌◌◌◌◌
Payout % — not applicable: no dividend——————
ROE %−455.8−182.2−84.8−54.8——
Shares out B0.060.020.020.010.010.00

Slide the table for earlier years. "—" not applicable · "◌" not available in our data.

More in this sector

Other companies filing in the same sector

Provenance

Company facts, as filed

How we verify · 0 failures in 27 reconciliationsAUDITED

Reconciled in 6 of the 6 fiscal years we could check. 26 checks were skipped: the balance sheet is not tagged before 2020. 13 checks were skipped: EPS is not tagged before 2020. 13 checks were skipped: revenue is not tagged before 2020.

EPS recomputationBalance-sheet identityGross profitBalance-sheet liquidityCurrency consistency0 failures
ActivitySurgical & Medical Instruments & Apparatus
Listed onNASDAQ
Incorporated inDelaware
Fiscal year endsDecember 31
SEC categoryemerging growth company, smaller reporting company
Data on record since2020

Share this section

Download image